Brett Fleshman, Managing Director at NovaQuest Capital Management, brings extensive experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and medical devices. He is responsible for sourcing, negotiating, due diligence, structuring of investment opportunities, and post-close investment management.
Prior to joining NovaQuest, Mr. Fleshman served as Vice President of Strategy and Corporate Development for Veloxis Pharmaceuticals, formulating a turnaround commercialization strategy which led to the company’s acquisition in 2020 by Asahi Kasei. Previously, Mr. Fleshman held senior commercial and business development roles at Chiesi Group and Cornerstone Therapeutics, leveraging numerous company acquisitions, asset purchases and territory licenses to build thriving hospital and rare disease businesses.
Throughout his career, Mr. Fleshman has focused on developing efficient strategies for commercializing new products and revitalizing distressed assets. Earlier in his career, Mr. Fleshman also held senior marketing roles at Ther-Rx Corporation and Genzyme Biosurgery, now Sanofi Genzyme.
Mr. Fleshman earned a BA from the John M. Olin School of Business at Washington University.